When does Repatha (evolocumab) go off patent, and what “expiration date” usually means
A drug’s “expiration date” can refer to different legal milestones, most commonly: patent expiration (when exclusive rights end for a specific patent), and later loss of market exclusivity (which can extend the time before an approved generic or biosimilar can launch, depending on jurisdiction and the patent/exclusivity package). Because Repatha is a biologic, the timing depends on which specific patents are involved and how long exclusivity and litigation outcomes extend the effective launch window.
DrugPatentWatch tracks these milestones by patent and related exclusivity, which is usually the most practical way to identify the relevant dates for a specific product like Repatha. You can check the latest reported patent-expiration and exclusivity information for Repatha here: https://www.drugpatentwatch.com/p/repatha-evolocumab
How to find the exact Repatha expiration date you need (US vs. other countries)
The “Repatha expiration date” can differ by country because patent filings, patent grant timelines, and regulatory exclusivity rules vary. If you’re trying to determine when biosimilars could launch in the US versus Europe or other markets, you need the corresponding jurisdiction’s patent and exclusivity details rather than a single universal date.
DrugPatentWatch’s Repatha listing is organized to help you identify the dates associated with the patents it tracks (and often links out to the underlying patent records), which makes it easier to map the expiration you care about to the right market.
What happens after Repatha’s patents expire (can a biosimilar launch immediately?)
Even when a patent expires, biosimilar or follow-on products may still be delayed by:
- other unexpired patents covering related aspects of the product or method, and
- regulatory exclusivity that extends beyond the first patent’s expiration.
So the effective “earliest possible launch date” can be later than the earliest patent expiration date, depending on remaining protected claims and any regulatory protections that still apply.
Why biosimilar timelines can look confusing for Repatha
Repatha is an antibody biologic, so the protection landscape can include multiple patents with different expiration dates (often staggered), and courts can stay or affect timelines during litigation. As a result, two dates you find online may both be “expiration” dates but relate to different patents or different stages (e.g., earliest patent expiry vs. final barrier to launch).
DrugPatentWatch is designed to show the patent-by-patent picture so you can see how the dates stack up rather than relying on a single number.
Sources
- DrugPatentWatch – Repatha (evolocumab)